Press Center

Dr.Signal BioTechnology company overcomes two major challenges in cell therapy and showcases the new 3AGTP technology at the medical exhibition.

The Taiwan Medical Technology Exhibition recently took place at the Nangang Exhibition Center, where Dr.Signal showcased its exclusive new technology "3AGTP." Deputy Premier of the Executive Yuan, Shen Rong-jin, and Vice Minister of the Ministry of Health and Welfare, Shi Chung-liang, were among the attendees. In recent years, through cell therapy and regenerative medicine, the use of active cells or genetically modified immune cells as drugs to treat complex diseases or to heal dysfunctional and damaged tissues has become a new trend in the medical field. However, there are still two major concerns in the development: insufficient stem cell manufacturing and production capacity.

To address these challenges, Dr.Signal has developed a new technology that utilizes automated cell processes to accelerate stem cell therapy and applications.

The potential for regenerative medicine is vast! Automated processes can meet industry demands. According to Research and Markets, the estimated compound annual growth rate (CAGR) of the global regenerative medicine market from 2020 to 2030 is projected to reach 13.99%, with a market size of $87.03 billion, including approximately $58 billion for cell preparations and cell therapy drug production, and $6.4 billion for gene therapy products. This indicates that cell and gene therapy will be crucial for the future development of the biomedicine industry.

The Chairman of Dr.Signal , Dr. Mi Hsin-wu, mentioned that the company has been investing in smart automated cell extraction, culture, and storage platform development for many years. They have standardized all laboratory cell preparation processes and automated these standardized processes, collecting digital transformation parameters. By utilizing AI to manage and compute these parameters, they have established an intelligent and automated cell preparation subcontracting process and commission development and manufacturing (CDMO) factory.

Dr. Mi Hsin-wu admitted that in the past, regenerative cells were cultivated manually, but for the industry to develop rapidly, manual processes alone cannot meet industry demands. It is essential to utilize automated processes to quantize and standardize advanced processes that comply with regulations to mass-produce cells with consistent quality. He uses information products as an example: laptops, mobile phones, and other 3C products in people's hands are all produced by automated factory production lines. If the cell industry can develop automated cell manufacturing processes, it can resolve the instability and potential contamination issues associated with manual culturing. This advancement would enable the cell industry to make significant leaps forward.

3AGTP Enables Remote Management to Maintain Optimal Production Mode. Dr.Signal stated that the new 3AGTP technology utilizes artificial intelligence (AI), augmented reality (AR), and automation (Auto) to conduct Good Tissue Practice (GTP) for cell tissue operations. The goal is to achieve digital cell processes and, along with Dr.Signal iCell Technology cloud big data, optimize and adjust the entire line's mechanism and process parameters at any time, achieving the best automatic work order and maximizing production scheduling.

Dr. Mi Hsin-wu added that the new 3AGTP technology allows for real-time quality control and immediate corrective notification. Even if the production line is in different regions or countries, it can be remotely monitored in real-time, providing automatic optimization strategic decisions to maintain cell production like information product production - with machines maintained in optimal operation 24 hours for cell production. Utilizing the 3AGTP technology can provide the best stem cell production capacity, allowing for large-scale stem cell production to meet industry demands, resolving the urgent issue of insufficient production capacity, accelerating the development and application of stem cell therapy, boosting the development of the biotechnology industry, and contributing to Taiwan's advancement in regenerative medicine industry.

Source: healthmedia